| Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Comparative Efficacy of Complement Inhibitors in Complement Inhibitor-Naïve PNH: A Systematic Review With Supportive Exploratory Network Meta-Analysis of Randomized Trials |
|
eJHaem |
Myelodysplastic Syndromes (MDS) |
| Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years |
|
Blood Advances |
Aplastic Anemia |
| Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment |
|
European Journal of Haematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy |
|
Annual Review of Pathology: Mechanisms of Disease |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clonal Hematopoiesis and therapy related MDS/AML |
|
Best Practice & Research. Clinical Heamatology |
Myelodysplastic Syndromes (MDS) |
| Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery? |
|
Leukemia & Lymphoma |
Aplastic Anemia |
| Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria |
|
Leukemia & Lymphoma |
Aplastic Anemia |
| Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience |
|
Leukemia & Lymphoma |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
